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Abstract The urokinase receptor (u-PAR), a protein anchored
to cell membrane by a glycosyl phosphatidylinositol, plays a
central role in cancer cell invasion and metastasis by binding
urokinase plasminogen activator (u-PA), thereby facilitating
plasminogen activation. Plasmin can promote cell migration
either directly or by activating metalloproteinases that degrade
some of the components of the extra cellular matrix. However,
the IGR-OV1-Adria cell line contains the u-PAR but does not
migrate even in the presence of exogenous u-PA, although the
parental IGR-OV1 cell line migrates normally in the presence of
u-PA. We therefore investigated the role of cell signalling for u-
PA induced cell locomotion. We show that cell migration induced
by u-PA^u-PAR complex is always associated with tyrosine
kinase activation for the following reasons: (1) the blockade of
the u-PAR by a chimeric molecule (albumin-ATF) inhibits not
only the u-PA-induced cell migration, but also the signalling in
IGR-OV1 line; (2) the binding of u-PA to u-PAR on non-
migrating IGR-OV1-Adria cells was not associated with tyrosine
kinase activation; (3) the inhibition of tyrosine kinase also
blocked cell migration of IGR-OV1. Therefore tyrosine kinase
activation seems to be essential for the u-PA-induced cell
locomotion possibly by the formation of a complex u-PAR^u-
PA with a protein whose transmembrane domain can ensure cell
signalling. Thus, IGR-OV1 and IGR-OV1-Adria cell lines
represent a good model for the analysis of the mechanism of u-
PA^u-PAR-induced cell locomotion.
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1. Introduction
Remodelling of extra cellular matrix (ECM) by plasmino-
gen activation is believed to play a prominent role in cancer
cell migration and in¢ltration in the surrounding tissue [1,2].
Urokinase plasminogen activator (u-PA) converts plasmino-
gen into plasmin, which activates a cascade of proteolytic
events, leading to collagen, laminin and ¢bronectin degrada-
tion [3]. Receptor for u-PA (u-PAR) captures u-PA at the cell
surface. U-PAR is a glycosyl phosphatidylinositol (GPI)-
linked cell surface protein [4] that is expressed in many tu-
mour cells while u-PA appears to be synthesised by the cells in
the stroma and is then bound to cancer cells which express the
u-PAR [5]. Binding of u-PA and plasminogen to their recep-
tors increases the rate of plasminogen activation by u-PA. The
simultaneous presence of u-PAR and plasminogen receptor on
the cell surface results in the assembly of a highly e¤cient
system of plasmin generation and protection from plasmin
inhibition [6]. The formation of plasmin initiates thereafter a
pericellular and oriented proteolysis thereby enhancing migra-
tion potential [7,8].
U-PA^u-PAR complex could also act in a plasminogen-in-
dependent pathway in various ways. For instance, u-PA is
said to activate the hepatocyte stimulating factor (HSF) [9].
Finally, recent evidence indicates that u-PAR is part of mo-
lecular complex capable of mediating adhesion to matrix com-
ponents as well as transcription of transmembrane signalling,
suggesting a cooperative interaction among receptors involved
in cell migration, adhesion and matrix degradation [10]. In
this work, we present a model which provides evidence that
the presence of u-PAR^u-PA complex on the cell surface is
not by itself enough to promote cell migration. In this model,
we show that the migration of ovarian cancer cell line (IGR-
OV1) is a u-PA dependent event while the derived cell line
(IGR-OV1-Adria) loses its ability to migrate despite an e¡ec-
tive binding of u-PA to u-PAR and plasmin generation on cell
surface, possibly due to an absence of signal transduction
associated with u-PA binding to u-PAR.
2. Material and methods
ATF-HSA chimeric protein is a Kluyveromyces-secreted u-PAR
antagonist which has been previously described and characterised
[11]. It is a genetic conjugate comprising human serum albumin
(HSA) linked to the 1^135 amino-terminal fragment (ATF) of human
urokinase.
2.1. Cancer cells
The ovarian cancer parental cell line (IGR-OV1) was grown in
tissue culture as previously reported [12]. The derived cell line
(IGR-OV1-Adria) was selected from IGR-OV1 cells, following acquis-
ition of resistance to adriamycin due to an over expression of the
MDR1 gene [13]. The cells were then cultured in RPMI medium
supplemented with 10% foetal calf serum (FCS), 2 mmol/l L-gluta-
mine, 10
5
IU/l penicillin, and 100 mg/l streptomycin (Gibco, Paisley,
Scotland, UK). The cells were cultured without FCS during 24 h prior
to experimental manipulation. For cell migration assays, the cells were
incubated for the 2 days of migration in the presence of 2% cell
growth supplement Ultrozer (Biosepra, Courbevoie-F), instead of
FCS. The rate of cell proliferation was identical for the two cell lines
irrespective for the presence or the absence of FCS.
Two cell lines, resistant to chemotherapy, were used as controls:
parental HL 60 and daunorubicin resistant HL 60, parental K 562
and adriamycin resistant K 562.
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2.2. Cell lysate
Cells from con£uent monolayers were washed with PBS and then
scrapped in PBS containing 1 mM EDTA. The cell pellets were then
re suspended (0.5U10
7
cells) in 0.5 ml of lysis bu¡er (10 mM Tris-
HCl, pH 8.1, 140 mM NaCl, 2 mM EDTA, 1 mM PMSF, 100 KIU
aprotinin, 0.01 mg/ml leupeptin and 1% Triton X-100). For further
detail see in Busso et al. [14]. Protein in the lysate was quantitated by
the DC protein assay kit (BioRad laboratories, USA) which does not
give an overestimation for samples containing detergents.
2.3. Determination of u-PA level
Several methods were used for u-PA evaluation.
2.3.1. U-PA activity. To the 96-well microtiter plate-attached con-
£uent cells (membrane-associated PA) or to 100 Wl of supernatant, or
cell lysate (3 cycles of freezing-thawing) were added 100 Wl of plasmin-
free plasminogen at 250 Wg/ml (Diagnostica Stago, France) (or 100 Wl
of phosphate bu¡er for control) and 50 Wl of the plasmin-sensitive
chromogenic substrate S2251 (Kabi, Sweden). Plasmin generated was
evaluated by its amidolytic activity on S-2251. The paranitroaniline
released from the substrate was measured by its absorbance at 405
nM. In order to di¡erentiate between t-PA and u-PA, the same experi-
ment was carried out in the presence of amiloride (1 mM ¢nal con-
centration), which inhibits only u-PA activity [15]. U-PA activity was
expressed as the di¡erence in the absorbance obtained in the presence
and in the absence of plasminogen.
2.3.2. Antigenic assay of u-PA. The antigenic assay of u-PA was
done in the cell lysates, by ELISA, technique previously described for
u-PA determination in ovarian tumour [16]. The results have been
expressed in O.D.
2.3.3. Immuno-histochemical determination on intact cells. The
cells were cultured in a glass chamber slide Lab-Tek (Nunc Inc.,
Naperville, IL) and then successively incubated for 1 h at 4³C ¢rst
with 1:100 diluted polyclonal anti-serum anti-u-PA (kindly given by
Pr. R. Lijnen, Leuven, Belgium), second with 1:50 diluted biotinylated
Ig anti-rabbit Ig (Amersham, les Ulis, France) and third with 1:50
diluted streptavidin-£uorescein (Amersham). Computer-assisted image
analysis of immuno histochemical £uorescence was performed using a
confocal scanning Laser microscope (ACAS 570, Meridian Instru-
ments, Okemos, MI) with a laser power of 20 W (wavelength excita-
tion: 488 nM, emission: 525 nM).
2.3.4. Zymography. Zymography was done as described by Gra-
nelli and Piperno [17].
2.4. Determination of u-PAR level
2.4.1. Biological evaluation. Cells were cultured on a 96-well mi-
crotiter plates, as described above. When the cells are con£uent, the
wells are carefully washed and then 200 Wl of urokinase at concen-
trations ranging from 0.5 to 2 U/ml (or bu¡er as control) were added
to each well. After an incubation period of 30 min at 4³C, the super-
natants were discarded and the cells were carefully washed 3 times
with PBS containing 1% bovine albumin. U-PAR level was evaluated
by measuring the u-PA bound to the cells, using synthetic substrate,
as described above.
2.4.2. Immuno-histochemical determination. U-PA bound to the
cells was eluted by 3 min incubation at room temperature with 0.1
M glycine-HCl bu¡er, pH 3, (for better availability of the epitopes
recognised by the antibody against u-PAR), and then rinsed with
several changes of PBS.
U-PAR was detected as previously described for u-PA using suc-
cessive incubations for 1 h at 4³C with polyclonal anti-u-PAR ob-
tained in the goat (Product 399 G, American Diagnostics, Greenwich,
CT), biotinylated Ig anti-goat Ig (Amersham) and streptavidin-£uo-
rescein (Amersham).
2.4.3. Antigenic assay. ELISA was performed in the cell lysates by
the Imubind u-PAR Strip-well ELISA kit from American Diagnostica
(Greenwich, CT), according to the procedure indicated by the manu-
facturer. The results are expressed in ng u-PAR/mg protein.
2.5. Determination of PAI-1 in cell lysate and in the supernatant of the
cells
This was evaluated by ELISA using Asserachrom PAI-1 (Diagnos-
tica Stago).
2.6. Cell migration
After reaching con£uence, cells were dislodged by a cell scraper, on
a standardised surface, washed 3 times with the culture medium in the
absence of foetal calf serum and then cultured with 2% Ultrozer G
containing the required growth factors (Biosepra, Courbevoie-F). The
cell migration was determined by measuring the displacement of the
edges after 24 and 48 h incubation [18]. It was expressed by the
number of cells which migrate into 10 mm
2
, 48 h after introducing
`the wound' into the con£uent monolayer.
Migration assays were also performed, using the IGR OV1 cells
incubated with two di¡erent tyrosine kinase inhibitors (either tyrphos-
tin at 50 WM (¢nal concentration) for 18 h or genistein at 10 WM for
48 h) and with an inhibitor of protein kinase C (calphostin C at 40
nM for 18 and 48 h), as described by Klemke et al. [19].
Migration of IGR-OV1-Adria was also performed using cells incu-
bated with u-PA at 2 IU/ml (¢nal concentration) during cell migra-
tion.
2.7. Analysis of signal transduction after u-PA addition to the cells
Two techniques were used. It was also done on cells incubated for
various periods of time from 5 to 60 min with u-PA at 2 IU/ml.
2.7.1. Immuno-histochemical determination on intact cells. Cells
were cultured in glass chamber slide and then ¢xed and permeabilized
with 0.5% triton X-100 and 3% paraformaldehyde for 5 min followed
by 30 min post-¢xation with 3% paraformaldehyde [20]. Tyrosine
phosphorylation was then analysed by immunocytochemistry by in-
cubating the cells at 4³C for 2 h using the monoclonal antibody
against phosphotyrosine from Santa Cruz Biotechnology (Santa
Cruz, CA). Immunoconjugate was detected as described above by
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Table 1
U-PA and u-PAR evaluations in IGR-OV1 and IGR-OV1-Adria cell lines
IGR-OV1 IGR-OV1-Adria
(meanþSD) (meanþSD)
u-PA
u-PA activity (OD)
a
Intact cells 0.869þ0.105 0.029þ 0.005
Lysed cells 1.594þ0.307 0.030þ 0.004
Conditioned medium 0.393þ0.057 0.056þ 0.023
u-PA antigen (OD)
b
Lysed cells 1.235þ0.212 0.129þ 0.012
u-PAR
Immunohistochemistry (£uorescence units)
a
Intact cells 1 919þ 396 2 470þ 337
ELISA (ng/mg of protein)
b
Lysed cells 103þ 14 119þ 12
U-PA activity was determined by adding plasminogen and S2251. Plasmin generation was measured as the OD after 2 h incubation at 37³C as
described in Section 2. U-PA antigen was determined by ELISA. U-PAR was determined by computer-assisted image analysis of immunohisto-
chemical £uorescence and by ELISA.
a
n=10.
b
n=5.
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incubating the cells at room temperature for 1 h at 4³C successively
¢rst with 1:50 activated biotinylated Ig anti-mouse Ig (Amersham)
and second with 1:50 diluted streptavidin-£uorescein (Amersham).
To analyse the e¡ect of PAR blockade on signal transduction, the
same experiment was performed after incubating the IGR-OV1 cells
for 30 min at 37³C with ATF-HSA (100 nM).
2.7.2. Western blot analysis. Samples (75 Wl) of cell lysates (2U10
6
cells) were electrophoresed on 10% SDS-PAGE under non-reducing
conditions and electroblotted to nitro-cellulose sheets which were sub-
sequently blocked with 1% bovine serum albumin in TBST bu¡er (10
mM Tris-HCl, pH 8.1, 150 mM NaCl, 0.05% Tween-20). Phospho-
tyrosyl-containing proteins were detected by incubating the nitro-cel-
lulose sheets for 2 h at room temperature successively with (1) mono-
clonal antibody against phosphotyrosine at 2 Wg/ml, (2) 1:50 activated
biotinylated Ig anti-mouse Ig (Amersham) and (3) 1:50 diluted strep-
tavidin-peroxidase (Amersham). All antibodies and streptavidin per-
oxidase were diluted in PBS containing 1% albumin. Before each
incubation, the blots were washed with 4 changes of PBS for 5 min
each. After washing, immunoperoxidase was detected by diaminoben-
zidine (DAB) (6 mg of tetrahydrochloride DAB in 10 ml of 50 mM
Tris bu¡er, pH 7.6, containing 10 Wl of 30% perhydrol). The blots
were developed at room temperature for 5 min and the reaction was
stopped by rinsing the gels several times with PBS.
3. Results and discussion
The results presented in Table 1 show that the u-PA ex-
pressed on the derived ovarian cancer cell line (IGR-OV1-
Adria) was much lower as compared to the parental cell
line, whatever the technique used (biological activity or im-
munological assay). This was also con¢rmed by immunohis-
tochemical analysis (not shown). Amiloride inhibited the PA
activity by more than 90%, indicating the speci¢city for the u-
PA. These results were also con¢rmed by zymography which
clearly showed that the parental cell line produced signi¢-
cantly more u-PA than the derived IGR-OV1-Adria cells.
This di¡erence was not due to varying amounts of PAI-1
secretion since no u-PA^PAI complex was detected in the
two cell lines by zymography (Fig. 1) and PAI-1 was not
detected by ELISA in either the conditioned medium or the
cell lysate of IGR-OV1 and IGR-OV1-Adria cells. We did not
¢nd any relationship between resistance to chemotherapy and
the loss of u-PA in cells, since other cell lines (HL 60 resistant
to daunorubicin, K562 resistant to adriamycin) contained the
same levels of u-PA as the corresponding parental cell lines
(results not shown).
However, IGR-OV1-Adria cells expressed u-PAR just as
well as IGR-OV1 cells, as demonstrated by both immunohis-
tochemical measurements using computer analysis image on
cell membrane and by ELISA in the lysed cells (Table 1).
Similarly, they exhibited almost identical capacity to bind
exogenous u-PA, demonstrating that u-PAR in both cell lines
is functional: after subtracting the basal level of u-PA, the
addition of exogenous u-PA induced a similar increase in
PA activity in the two cell lines, as evaluated by plasminogen
activation (results not shown).
U-PA/u-PAR is involved in cancer cell migration and inva-
sion. Since, in the absence of u-PA secretion, exogenous u-PA
provided by stromal cells could be implicated in cancer cell
invasion by binding to u-PAR, we analysed in this work the
cell migration of parental and derived cell line. After wound-
ing the con£uent culture, cell displacement was measured by
following the wound repair after 48 h. With IGR-OV1, a total
wound repair was observed in 48 h, partially due to plasmin
generation since addition of aprotinin (1 WM), a potent plas-
min inhibitor, inhibited 57% cell migration. IGR-OV1-Adria
did not migrate even after 48 h (Table 2). Interestingly, the
inability of IGR-OV1-Adria cells to migrate was not corrected
by the addition of exogenous u-PA, even at high concentra-
tions (2^20 U/ml), despite the concomitant increase in u-PA
activity expressed on the cell surface. This observation sug-
gests that u-PA/u-PAR mediated extracellular proteolysis is
not su¤cient for inducing cell migration. Therefore we hy-
pothesised that u-PA binding to u-PAR can also induce cell
locomotion by inducing a cytoskeletal rearrangement related
to a cell signalling via tyrosine kinase activation. This hypoth-
esis was supported by our results shown in Fig. 2, on both
migrating IGR-OV1 (Fig. 2A) and non-migrating IGR-OV1-
Adria cell lines (Fig. 2B): an expression of phosphotyrosine
was noted on IGR-OV1 in basal conditions which increased
further after u-PA addition; interestingly, the expression of
phosphotyrosine was very low in IGR-OV1-Adria cells even
when u-PA was added. As presented in Fig. 2C, the expres-
sion of the phosphotyrosine on IGR-OV1 was inhibited by
adding the u-PAR blocker 9 ATF-HSA 9 at 100 nM, con-
centration which was known to inhibit cell migration [11].
The absence of expression of phosphotyrosine in IGR-OV1-
Adria was also evidenced by Western blot analysis since phos-
photyrosine was undetectable in cell extracts obtained from
IGR-OV1-Adria cells even after the incubation of cells with u-
PA, while in IGR-OV1 cell extracts, the expression of phos-
photyrosine was evident in untreated cells and increased after
incubation with u-PA (Fig. 3). The di¡erence observed in the
basal tyrosine phosphorylation pattern in both cell lines was
FEBS 18831 12-9-97
Fig. 1. Zymography of cell extracts for plasminogen activator detec-
tion. Lane A: u-PA. Lane B: IGR-OV1 cell extract. Lane C: IGR-
OV1-Adria cell extract. 10
9
cells/ml were lysed in the sample bu¡er
containing 4 M urea and 2% SDS. 20 Wl of the di¡erent extracts
were applied to the gel and run for 4 h at 20 mA. At the end of
the electrophoresis, gels were incubated for 1 h with 2.5% Triton-
X100 under gentle agitation and then extensively washed in water.
The gels were applied to a plasminogen-rich ¢brin plate and incu-
bated for 16 h in moist atmosphere and then the gels were photo-
graphed. The PA were identi¢ed according to their molecular
weights. HMW u-PA: high molecular weight u-PA. LMW u-PA:
low molecular weight u-PA.
Table 2
Migration of IGR-OV1 and IGR-OV1-Adria: dependence of cell
signalling (tyrosine phosphorylation)
Cell tested Number of cells which migrated
in 10 mm
2
of wounded area in 48 h
MeanþSD (n=4)
IGR-OV1 300þ120
IGR-OV1+Aprotinin 1 WM 130þ 40
IGR-OV1+Tyrphostin
a
74þ 20
IGR-OV1+Genistein
a
20þ 7
IGR-OV1+Calphostin
a
280þ100
IGR-OV1-Adria 60þ 40
IGR-OV1-Adria+u-PA
b
70þ 50
a
Concentration and incubation time are indicated in Section 2.
b
2 IU/ml.
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not attributed to a di¡erent cell proliferation rate, since it was
identical for the two cell lines.
Furthermore, in the presence of speci¢c inhibitors of tyro-
sine kinases (tyrphostin and genistein), IGR-OV1 cells largely
lost their ability to migrate (Table 2), suggesting that tyrosine
kinase activation is important for cell migration. Addition of
calphostin, an inhibitor of protein kinase C, did not induce
any modi¢cation in cell displacement.
Because u-PAR is anchored to the membrane by a glycosyl
phosphatidylinositol (GPI) anchor [21^23], it was assumed
that u-PA activates a transmembrane signal through a third
molecule that is associated with u-PAR instead of transducing
this signal by u-PAR itself [24]. Further study will be needed
to determine if the defective tyrosine kinase activation after
incubation of IGR-OV1-Adria cells with u-PA is related to a
defective association of u-PAR with the protein whose trans-
membrane domain can ensure cell signalling.
We conclude that the absence of tyrosine phosphorylation
of cytosolic proteins in IGR-OV1-Adria, when u-PA binds to
u-PAR, may impair the rearrangement of cytoskeleton neces-
sary for cell migration and could explain the absence of IGR-
OV1-Adria migration even when u-PA is associated to u-
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Fig. 2. Phosphotyrosine expression in IGR-OV1 and IGR-OV1-Adria cell lines. A: IGR-OV1. a: Basal level of phosphotyrosine (1980 £uores-
cence units). b^d: Level of phosphotyrosine in IGR-OV1 previously incubated with u-PA for 15, 30 or 60 min, respectively (b= 4212,
c = 21 852, d= 15 979 £uorescence units). B: IGR-OV1-Adria. a: Basal level of phosphotyrosine (425 £uorescence units). b^d: Level of phospho-
tyrosine in IGR-OV1-Adria previously incubated with u-PA for 15, 30 or 60 min, respectively (b= 428, c = 412, d= 509 £uorescence units). C:
u-PAR blockade in IGR-OV1 cell line. a: IGR-OV1 cell line. b: IGR-OV1 cell line incubated for 30 min with 100 nM ATF-HSA. Fixed and
permeabilized cells were incubated for 90 min at room temperature with 1:300 diluted monoclonal antibody against phosphotyrosine, after ex-
tensive washing, immunoconjugate was detected by adding successively for 60 min 1:50 diluted biotinylated Ig anti-mouse Ig and 1/50 streptavi-
din-£uorescein. Image analysis of immunohistochemical £uorescence was performed using a confocal laser microscope (wavelength excitation:
488 nM and emission: 525 nM).
Fig. 3. Assessment of phosphotyrosine by Western blot in the two
cell lines incubated in the presence or absence of u-PA. Lane A:
Standard molecular weights (123 000-89 000-67 000-49 000-37 500 and
34 000). Lane B: Lysate from IGR-OV1-Adria cells in the absence
of exogenous u-PA. Lane C: Lysate from IGR-OV1-Adria previ-
ously incubated for 30 min with u-PA (2 IU/ml). Lane D: Lysate
from IGR-OV1 cells in the absence of exogenous u-PA. Lane E:
Lysate from IGR-OV1 cells previously incubated for 30 min with u-
PA (2 IU/ml).
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PAR. In addition, because cytoskeletal reorganization induces
u-PA gene expression [25], the absence of cell signalling ob-
served in IGR-OV1-Adria could also explain the defective u-
PA secretion of these cells.
We provide here a cell model that will be useful for identi-
fying these molecules which activate transmembrane signal
and cell locomotion in response to u-PA action on the cells.
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